Improving the Lives of Patients with Cancer

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other diseases.

FAST FACTS

We are a commercial-stage, global pharmaceutical company with one FDA-approved drug in three oncology indications and three additional drug candidates in clinical development.

We have been working for over 10 years to advance research and development in cancer therapeutics.

Our internationally diverse team speaks 23 languages, with headquarters outside Boston and satellite offices in Israel and Germany.

We are an immigrant female-founded biotech company where over 50% of our leadership positions are filled by women.

We have been serving patients since 2012 when our novel drug selinexor first entered clinical trials and we continue to be inspired by these courageous patients and their families.

OUR MISSION

We seek to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions.

At Karyopharm, we support a culture of innovation, courage, urgency, resiliency and energy (ICURE) with our employees and collaborators.

OUR BLUEPRINT FOR SUCCESS

INNOVATION

We encourage employees to develop creative, yet practical ideas that don't simply rely on things that have been done in the past.

COURAGE

We challenge the norms to solve problems and advance science in order produce the best outcomes for patients.

URGENCY

We approach our tasks with drive, passion and dedication with an understanding that patients battling cancer are relying on us every day.

RESILIENCE

We remain committed to persevere even in the face of challenges and adversity.

ENERGY

We approach opportunities and tackle challenges with a greate sense of enthusiasm and determination.

OUR SCIENCE

Science and innovation are the core principles by which we operate. We are pioneering novel science to harness each cell's own natural defense mechanisms to prevent the initiation and growth of cancers. We are the leader in innovative science to advance cancer therapy by targeting the regulation of critical proteins that need to be located in a cell's nucleus in order to function properly. This approach is synergistic with current anti-cancer treatments making it an ideal partner for future combination therapy approaches.



OUR APPROACH

Our clinical development strategy for XPOVIO® has been to innovate with the purpose of helping difficult-to-treat patient populations and then expanding into larger patient groups and tumor types. The mechanisms of action of our novel nuclear export inhibitors target a foundational aspect of cancer biology which may allow them to be used against very wide variety of different tumors. Our development began in hematologic malignancies and and we have expanded our clinical trials into a variety of solid tumors.

We see our pipeline of products as a critical partner of choice to be combined with other cancer medicines in a host of different types of cancer and other serious diseases.

OUR STORY

We began in 2008 with a vision of pioneering a new approach to treating patients with cancer and other serious diseases. Our novel approach to treating cancer involves targeting a cancer cell's nucleus to prevent the development of a disease. For this reason, our name is based on the suffix 'karyo', which means nucleus.

In 2019, we received our first accelerated approval in penta-refractory multiple myeloma. We received a second accelerated approval in 2020 for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL).

We received an expanded approval for XPOVIO in December of 2020 to now include patients with multiple myeloma as early as first relapse.

In 2020, we also had a successful phase 3 study in heavily pretreated patients with a rare tumor type called dedifferentiated liposarcoma.

We are undertaking numerous clinical trials with a bright future of potential FDA approvals yet to come.

Karyopharm works every day, innovating the science needed to improve the lives of patients with cancer.

BELOW IS A BRIEF TIMELINE OF OUR COMPANY HISTORY.

2008

Company founded by Drs. Sharon Shacham and Michael Kauffman to develop potential new drugs which target the regulation of certain proteins in the cell nucleus as a way to treat cancer and other diseases

2010

First evidence of anti-cancer activity of selinexor in mice

2012

First patient treated with selinexor in a clinical trial

2013

Karyopharm becomes publicly traded company with shares listed on Nasdaq

2019

Selinexor receives first accelerated approval by FDA for patients with relapsed or refractory multiple myeloma (a form of blood cancer) under the brand name XPOVIO

2020

XPOVIO receives second accelerated approval by FDA for patients with relapsed or refractory diffuse large B-cell lymphoma (another form of blood cancer)

Company completes successful phase 3 study in heavily pretreated dedifferentiated liposarcoma.

On December 18, XPOVIO received expanded approval in multiple myeloma, which fundamentally changes the commercial profile of XPOVIO and Karyopharm. The previous approval limited XPOVIO to roughly 6,000 patients with penta-refractory disease. The expanded approval increases XPOVIO as an option to more than 39,000 patients who have received at least one prior therapy (including the original 6,000).

2021 AND BEYOND

Karyopharm hopes to expand XPOVIO's approved indications in the U.S. into earlier stage disease, in combination with other anticancer drugs, and in new tumor types (particularly solid tumor indications).

In January, we received our first positive opinion from European regulators and are working towards our first regulatory approvals in the European Union, and we have received regulatory approval in Israel.

Our team works relentlessly every day to develop innovative drugs to help treat patients with certain blood cancers or solid tumor malignancies. Since our beginning, we have been committed to changing lives and defeating cancer through science and innovation.

OUR FOUNDERS

Sharon Shacham, PhD, MBA

Dr. Shacham founded Karyopharm in 2008 and has served as our Chief Scientific Officer and President since December 2012. From 2010 to 2012, Dr. Shacham served as our Chief Scientific Officer and Head of Research and Development, and prior to that, as our President and Chief Executive Officer.

Michael Kauffman, MD, PhD

Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and has served as our Chief Executive Officer since January 2011 and as a director since 2008. He is board certified in internal medicine.